Moors & Cabot Inc. Has $259,000 Holdings in Alkermes plc (NASDAQ:ALKS)

Moors & Cabot Inc. lifted its stake in shares of Alkermes plc (NASDAQ:ALKS) by 12.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,997 shares of the company’s stock after buying an additional 1,028 shares during the period. Moors & Cabot Inc.’s holdings in Alkermes were worth $259,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ALKS. Venturi Wealth Management LLC acquired a new position in shares of Alkermes during the fourth quarter worth $25,000. Blue Trust Inc. increased its holdings in shares of Alkermes by 2,231.5% during the fourth quarter. Blue Trust Inc. now owns 1,702 shares of the company’s stock worth $49,000 after buying an additional 1,629 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Alkermes by 558.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company’s stock worth $85,000 after buying an additional 2,502 shares in the last quarter. KBC Group NV increased its holdings in Alkermes by 18.8% in the third quarter. KBC Group NV now owns 4,890 shares of the company’s stock valued at $137,000 after purchasing an additional 774 shares during the period. Finally, Cornerstone Investment Partners LLC acquired a new stake in Alkermes in the fourth quarter valued at $203,000. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Alkermes

In other news, EVP Craig C. Hopkinson sold 144,419 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the transaction, the executive vice president now owns 57,875 shares of the company’s stock, valued at $2,056,298.75. This represents a 71.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 4.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ALKS. HC Wainwright restated a “neutral” rating and issued a $46.00 price objective on shares of Alkermes in a report on Thursday, February 13th. StockNews.com upgraded Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft began coverage on Alkermes in a report on Tuesday, February 11th. They issued a “buy” rating and a $40.00 price objective for the company. UBS Group upgraded Alkermes from a “sell” rating to a “neutral” rating and increased their price objective for the company from $21.00 to $38.00 in a report on Tuesday, March 4th. Finally, Royal Bank of Canada began coverage on Alkermes in a report on Thursday. They issued a “sector perform” rating and a $40.00 price objective for the company. Four analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Alkermes has a consensus rating of “Moderate Buy” and a consensus price target of $38.46.

Alkermes Trading Up 1.2 %

Shares of Alkermes stock opened at $34.03 on Monday. The business has a 50-day moving average price of $32.38 and a two-hundred day moving average price of $29.86. Alkermes plc has a 1-year low of $22.90 and a 1-year high of $36.45. The company has a market cap of $5.53 billion, a P/E ratio of 15.68, a PEG ratio of 2.20 and a beta of 0.62.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. Equities research analysts forecast that Alkermes plc will post 1.31 EPS for the current fiscal year.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.